Submission Deadline: September 30, 2026

Guest Editor:

Dr. Hengrui Liu  
University Of Cambridge

 

Special Issue Information:

Dear Colleagues,

In the era of precision immuno-oncology, identifying robust biomarkers that can predict and monitor response to immunotherapy is crucial for optimizing patient outcomes. This Topical Collection, Immunotherapy-Specific Biomarkers and Targets in Cancer, focuses on the discovery and clinical relevance of biomarkers and molecular targets specifically linked to cancer immunotherapy.

We welcome original research, reviews, and perspectives that address immune-related biomarkers such as PD-1/PD-L1 expression, tumor mutational burden (TMB), microsatellite instability (MSI), neoantigen load, immune cell infiltration patterns, and predictors of immune-related adverse events (irAEs). We also encourage submissions exploring multi-omics integration, machine learning-based biomarker discovery, and development of companion diagnostics for immune checkpoint inhibitors, cancer vaccines, adoptive cell therapies, and other immunotherapeutic modalities.

Studies that clarify resistance mechanisms to immunotherapy, identify novel immune-regulatory pathways, or propose biomarker-guided combination strategies are particularly encouraged. This Collection aims to bridge cutting-edge immunologic insights with clinical application, supporting the development of more individualized, effective, and safer cancer immunotherapies. For planned papers, a title and short abstract can be sent to the Editorial Office shy@ukscip.com for announcement on this website. 

Guest Editor(s)
Dr. Hengrui Liu

Keywords:

• Cancer
• Cancer genetics
• Biomarker
• Therapeutic target